8-K: Oncocyte Reports First Quarter 2024 Financial Results, Highlights Bio-Rad Partnership and Reduced Cash Burn

Oncocyte announced its first quarter 2024 financial results, highlighting a new partnership with Bio-Rad, progress in commercializing its GraftAssure test, and a reduction in cash burn.

Summary

• Oncocyte Corporation reported its financial results for the first quarter of 2024, ending March 31, 2024.
• The company announced a global commercialization partnership with Bio-Rad Laboratories, Inc.
• Oncocyte is on track to ship research use only (RUO) GraftAssure transplant monitoring test kits to initial customers in Asia, the U.S., and the EU in the second quarter of 2024.
• The company raised $15.8 million in gross proceeds from an equity private placement, with Bio-Rad purchasing 8.99% of Oncocyte.
• Cash burn was reduced to $3.9 million, reflecting a capital-efficient business model.
• Net revenue for the quarter was $176,000, a 41% decrease compared to the same period in 2023, primarily due to decreased revenue from the Pharma Services business.
• The total cost of revenues was $274,000, a 5% decrease compared to the same period in 2023.
• Research and development expenses increased by 2% to $2.2 million.
• Sales and marketing expenses increased by 22% to $846,000.
• General and administrative expenses decreased by 22% to $2.7 million.
• The loss from operations was $9.3 million, compared to income from operations of $5.9 million in the same period of 2023, primarily due to a change in the fair value of contingent consideration.
• Excluding the change in fair value of contingent consideration, the loss from operations decreased by 52% compared to 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the Bio-Rad partnership and reduced cash burn are positive, the significant decrease in revenue and the shift to an operating loss are concerning. The company is making progress but faces challenges.

Positives

• The partnership with Bio-Rad is expected to accelerate the launch of GraftAssure and expand commercial reach.
• The company is on track to ship GraftAssure RUO test kits in Q2 2024.
• The $15.8 million capital raise strengthens the company's financial position.
• The reduction in cash burn to $3.9 million demonstrates improved cost control.
• The company is developing regulated products including VitaGraft Kidney IVD.
• The company's technology has been selected to support multiple Phase 2 clinical studies by pharmaceutical companies.

Negatives

• Net revenue decreased by 41% compared to the same period in 2023.
• The company reported a loss from operations of $9.3 million, compared to a profit of $5.9 million in the same period of 2023.
• The loss from operations was primarily due to the unrealized noncash change in fair value of contingent consideration.

Risks

• The company faces risks inherent in the development and commercialization of diagnostic tests.
• There is uncertainty in the results of clinical trials and regulatory approvals.
• The company's third-party supplied blood sample analytic system may not provide consistent results on a commercial scale.
• Potential interruptions to supply chains could impact operations.
• The company may need to obtain future capital.
• There are risks associated with strategic transactions, such as the potential failure to realize anticipated benefits.

Future Outlook

Oncocyte anticipates shipping GraftAssure RUO test kits to initial customers in Q2 2024 and expects to achieve numerous critical commercial and regulatory milestones throughout 2024 and into 2025. The company also plans to continue developing its oncology diagnostics pipeline products, DetermaIO and DetermaCNI.

Management Comments

• Josh Riggs, Oncocyte's CEO, stated that the company made significant progress toward commercializing its innovative blood-based diagnostic tests in the first quarter of 2024.
• He believes that the collaboration with Bio-Rad is pivotal for the upcoming launch of the GraftAssure RUO transplant rejection diagnostic test kit.
• He also stated that the partnership is central to the company's mission of developing and providing accessible point of care diagnostics and continuous innovation in transplant rejection monitoring.

Industry Context

The partnership with Bio-Rad and the focus on transplant monitoring align with the growing trend of precision diagnostics and personalized medicine. The development of point-of-care diagnostics is also a key area of focus in the industry.

Comparison to Industry Standards

• The 41% decrease in revenue is concerning and may indicate challenges in the commercialization of their products compared to other diagnostic companies.
• The reduction in cash burn to $3.9 million is a positive sign, as many biotech companies struggle with high operating costs.
• The partnership with Bio-Rad is a significant development, as it provides access to a larger distribution network and expertise, similar to other successful collaborations in the diagnostics industry.
• The development of IVD kits for FDA submission is a standard practice for companies in this sector, and the progress in this area is crucial for long-term success.
• The selection of Oncocyte's technology for Phase 2 clinical studies by pharmaceutical companies is a positive indicator of the potential of their assays, similar to other companies that have successfully partnered with pharmaceutical firms.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the operating loss.
• Employees may be impacted by the company's cost-control measures.
• Customers may benefit from the launch of GraftAssure and other diagnostic tests.
• Suppliers may be affected by changes in the company's operations.
• Creditors may be impacted by the company's financial performance.

Next Steps

• Shipment of GraftAssure RUO test kits to initial customers in Q2 2024.
• Continued development of regulated products, including VitaGraft Kidney IVD.
• Advancement of oncology diagnostics pipeline products, DetermaIO and DetermaCNI.
• Filing of the quarterly Form 10-Q with the Securities and Exchange Commission on May 15, 2024.

Key Dates

Keywords

Oncocyte, GraftAssure, Bio-Rad, transplant monitoring, diagnostics, financial results, equity private placement, cash burn, VitaGraft, DetermaIO, DetermaCNI